

# Silvia Ingala

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8234033/publications.pdf>

Version: 2024-02-01

33  
papers

427  
citations

840776

11  
h-index

839539

18  
g-index

35  
all docs

35  
docs citations

35  
times ranked

731  
citing authors

#	ARTICLE	IF	CITATIONS
1	Degenerative adversarial neuroimage nets for brain scan simulations: Application in ageing and dementia. <i>Medical Image Analysis</i> , 2022, 75, 102257.	11.6	13
2	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100128.	0.9	0
3	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease. <i>European Radiology</i> , 2022, 32, 7789-7799.	4.5	3
4	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. <i>NeuroImage: Clinical</i> , 2022, 35, 103106.	2.7	9
5	White matter microstructure disruption in early stage amyloid pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12124.	2.4	16
6	DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1627-1635.	4.7	17
7	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.8	44
8	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , 2021, 3, fcab201.	3.3	14
9	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
10	Tau and synaptic biomarkers but not amyloid $\beta$ are associated with cerebral perfusion in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
11	Prediction of amyloid pathology in cognitively unimpaired individuals using structural MRI. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
12	Neuroimaging-derived phenotypes in the European Prevention of Alzheimer Dementia (EPAD) Cohort Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
13	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
14	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 8.	6.2	12
15	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.1	55
16	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. <i>Alzheimer's and Dementia</i> , 2020, 16, e037912.	0.8	0
17	ExploreQC: A toolbox for MRI quality control in the EPAD multicentre study. <i>Alzheimer's and Dementia</i> , 2020, 16, e041952.	0.8	0
18	Amyloid-dependent association of grey matter network disruptions with phospho $\tau$ in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044739.	0.8	0

#	ARTICLE	IF	CITATIONS
19	ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies. <i>NeuroImage</i> , 2020, 219, 117031.	4.2	80
20	Response: Brain military enhancement. <i>Neuroradiology</i> , 2020, 62, 547-547.	2.2	0
21	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. <i>Neurobiology of Aging</i> , 2020, 95, 104-114.	3.1	15
22	Brain military enhancement. <i>Neuroradiology</i> , 2020, 62, 283-300.	2.2	16
23	White matter integrity disruption in early amyloid accumulators. <i>Alzheimer's and Dementia</i> , 2020, 16, e043021.	0.8	0
24	Medial temporal lobe atrophy and posterior atrophy scales normative values. <i>NeuroImage: Clinical</i> , 2019, 24, 101936.	2.7	12
25	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101954.	2.7	42
26	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 45.	6.2	19
27	The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study. <i>European Radiology</i> , 2018, 28, 1215-1226.	4.5	8
28	P1401: INVESTIGATING ARTERIAL SPIN LABELING AS A LARGE VESSEL CORRELATE OF SVD, AD, AND PD. <i>Alzheimer's and Dementia</i> , 2018, 14, P456.	0.8	3
29	ICP19: POSTERIOR ATROPHY SCALE: NORMATIVE VALUES FOR ITALIAN POPULATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P101.	0.8	0
30	P3348: POSTERIOR ATROPHY SCALE: NORMATIVE VALUES FOR ITALIAN POPULATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1217.	0.8	0
31	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	6.2	46
32	P2458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P895.	0.8	0
33	[P1400]: USING SUBTRACTION MRI TO IMPROVE THE DETECTION OF AMYLOID-RELATED IMAGING ABNORMALITIES WITH EDEMA OR EFFUSION (ARIA) IN PATIENTS AFFECTED BY ALZHEIMER'S DISEASE RECEIVING IMMUNOTHERAPY: AN INTER-OBSERVER STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P425.	0.8	0